3Hung MC,LauYK. Basic seience of HER2/neu:a review[J].{H}Seminars in Oncology,1999,(4 Suppl 12):51-59.
4Fornier M,Esteva FJ,Seidman AD. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer[J].{H}Seminars in Oncology,2000,(6):38-45.
1Vogel CL,Cobleigh MA,Tripathy D,et al.First-line herceptin monotherapy in metastatic breast cancer[J].Oncology,2001,61(Suppl 2):37-42.
2Fornier M,Esteva FJ,Seidman AD.Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer[J].Semin-Oncol,2000,27:38-45.
3Slamon DJ,Leyland-Jones B,Fuchs H,et al.Use of chemotherapy plus a monoclonal antibody against Her-2 for metastatic breast cancer that overexpresses Her-2[J].N Engl J Med,2001,344(11):783-792.
4Gralow JR.Optimizing the treatment of metastatic breast cancer[J].Breast Cancer Res Treat,2005,89(Suppl1):S9-S15.
5Pegram MD,Lopez A,Konecny G,et al.Trastuzumab and chemotherapeutics:drug interactions and synergies[J].Semin Oncol,2000,27(suppl11):21-25.
6Burstein HJ,Kuter I,Campos SM,et al.Clinical activity of trastuzumab and vinorelbine in women with Her-2-overexpressing metastatic breast cancer[J].J Clin Oncol,2001,19(10):2722-2730.
7Domenech GH,Vogel CL.A review of vinorelbine in the treatment of breast cancer[J].Clin Breast Cancer,2001,2(2):113-128.
8Vogel CL,Cobleigh MA,Tripathy D,et al.Efficacy and safety of trastuzumab as a single agent in first-line treatment of Her-2 overexpressing metastatic breast cancer[J].J Clin Oncol,2002,20(3):719-726.
9Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001,344:783-792.
10Cook-Bruns N. Retrospective analysis of the safety of Hereeptin immunotherapy in metastatic breast cancer. Oncology, 2001,61:S58-S66.
